Finoriq research workspace
Kymera Therapeutics, Inc. (KYMR) Historical Metrics
Kymera Therapeutics, Inc. engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical. Review KYMR valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Company
- Kymera Therapeutics, Inc. (KYMR)
- Ticker
- KYMR
- Market Cap
- $9.3B
- Latest Price
- $112.83
- Industry
- Biotech & Pharma
Kymera Therapeutics, Inc. (KYMR) Current Valuation Metrics
Static valuation preview for Kymera Therapeutics, Inc. (KYMR). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 240x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -3.3% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -2.5% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 5.97x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.